RACE : Rapid Dose Escalation of Quetiapine versus Conventional Escalation in the Treatment of Patients with Acute Schizophrenia – a Multicentre, Double-blind, Parallel group, Randomized Study The primary objective for the study is to evaluate the safety and tolerability of IR (Immediate-Release) quetiapine in a rapid escalation scheme (300 mg on day 1, 600 mg on day 2 and 800 mg on day 3) ...

• Country None
• organs None
• Specialty None

Addition of vandetanib to standard therapy (pegliposomal doxorubicin) in patients with recurrent ovarian cancer. A multi-centre, non-randomized, open phase I/randomized phase II study to evaluate the tolerability and safety of once daily oral Vandetanib 100 mg when added to standard therapy (pegliposomal doxorubicin 50 mg/m2 iv every 4 weeks) compared to standard therapy alone (peg...

• Country None
• organs None
• Specialty None

The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorders with or without Psychotic Symptoms The main (primary) objective of this study is to evaluate the efficacy of quetiapine in the treatment of postpartum depressive disorders in female patients with or without psychotic symptoms. The corr...

• Country None
• organs None
• Specialty None

A randomized, open, parallel-group, multi-centre, phase IV study to evaluate the efficacy of three different patient management strategies with and without esomeprazole 20 mg during a 3 months maintenance phase following an initial 4-weeks acute treatment phase in subjects with symptoms thought to be GERD related To compare the efficacy of three different long-term treatment strategies in primary care setting, separately within different levels of symptom load according to clinical judgement at baseline (Visit...

• Country None
• organs None
• Specialty None

A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated with Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in a Naturalistic Setting The primary objective of this study is to demonstrate the non-inferiority of quetiapine XR to risperidone assessed at month 6 in terms of responder rate using the self-report instrument SWN-K.

• Country None
• organs None
• Specialty None